News


Sygnature Discovery receives a prestigious Queen’s Award for Enterprise

  21 April 2017 – Nottingham, UK – Sygnature Discovery has today been recognised with one of the UK’s most prestigious business awards – the Queen’s Award for Enterprise, International Trade. Today the company employs over 150 dedicated scientists who research potential new medicines to treat a host of debilitating and often fatal diseases. This […]

First look inside Sygnature Discovery’s new £30 million HQ – the “Discovery Building”

10th April 2017, Nottingham, UK – Dr Jonathan Williams, COO, has given the “Nottingham Post” a tour of the “Discovery Building”, Sygnature’s new “landmark” facility located in BioCity Nottingham.  The company will begin the move into the new, state-of-the-art building later this month. Dr Williams told the “Nottingham Post”: “After Oxford, Cambridge and London, Nottingham […]

Sygnature Discovery ranked in FT1000: The Financial Times list of Europe’s 1,000 fastest-growing companies

7th April 2017 – Nottingham, UK – Sygnature Discovery has been ranked 906th in the Financial Times FT1000 . The FT1000 lists the 1,000 companies in Europe that have achieved the highest percentage growth in revenues between 2012 and 2015. As the Financial Times describes it, “Innovative and fast-growing companies are the driving force of the […]

Double celebration for TopiVert and Sygnature Discovery as two drug candidates begin clinical trials

29th March 2017 – Nottingham and London, UK – One of Sygnature Discovery’s long-term clients, TopiVert Pharma, has recently initiated clinical trials with TOP1288 and TOP1630.  Both compounds were first synthesised at Sygnature during the successful collaboration.  TOP1288 and TOP1630 are Narrow Spectrum Kinase Inhibitors (NSKIs).  NSKIs target several important kinases in the signalling cascade […]

Keapstone Therapeutics and Sygnature Discovery collaborate to discover new therapies for Parkinson’s and Motor Neuron Disease

14th March 2017 – Sheffield, London and Nottingham, UK – Keapstone Therapeutics, a new biotech company formed by the University of Sheffield and Parkinson’s UK to develop new drugs for Parkinson’s and other neurodegenerative diseases, and Sygnature Discovery, the UK’s largest independent provider of integrated drug discovery resource and expertise, today announced they will collaborate […]

Page 2 of 1212345...10...Last »
Copyright © 2017 Sygnature Discovery

Website built by AtomicMedia - Design by Freestyle.